Core Viewpoint - Federal Pharmaceutical (03933) has seen a stock increase of over 3%, currently trading at 13 HKD with a transaction volume of 50.78 million HKD, following the announcement of successful Phase II clinical trial results for its innovative drug UBT251 in overweight/obese patients in China [1] Group 1: Company Developments - Federal Pharmaceutical's wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has completed Phase II clinical research for its self-developed innovative drug UBT251 injection [1] - The Phase II weight loss data for UBT251 (GLP-1/GIP/GCGR) has shown impressive results, with a weight loss rate at 24 weeks under lower dosage outperforming Eli Lilly's retatrutide [1] - The safety profile of UBT251 indicates mostly mild to moderate side effects, primarily gastrointestinal reactions [1] Group 2: Market Outlook - Huatai Securities expresses optimism regarding the strong Phase II data from China, suggesting that the recent initiation of global Phase II data by Novo Nordisk may enhance the certainty of UBT251's overseas sales potential [1]
港股异动 联邦制药(03933)涨超3% UBT251国内II期减重数据整体表现惊艳 机构看好其海外销售空间